AKT1 belongs to a family of serine-threonine protein kinases which also includes AKT2 and AKT3. AKT1 plays a key role in multiple cell processes, including growth, proliferation, survival, and angiogenesis. AKT1 acts as a downstream mediator of phosphatidylinositol 3-kinase (PI3K) (Figure 1).
Figure 1. Schematic of the MAPK and PI3K pathways. Growth factor binding to receptor tyrosine kinase results in activation of the MAPK signaling pathway (RAS-RAF-MEK-ERK) and the PI3K pathway (PI3K-AKT-mTOR). The letter "K" within the schema denotes the tyrosine kinase domain.
Last Updated: June 1, 2012
Somatic mutations in AKT1 have been found in a fraction of breast cancers (see Table).
|Gene Mutation||Invasive Breast Cancer||Hormone Receptor Positive (ER+ and/or PR+) Invasive Breast Cancer||HER2 positive Invasive Breast Cancer||Triple-negative Invasive Breast Cancer|
|AKT1||4% (O'Brien et al. 2010)||3.2% (Stemke-Hale et al. 2008)||<1% (Stemke-Hale et al. 2008)a||<1% (Stemke-Hale et al. 2008)a|
a small sample size <100 patients
Last Updated: August 8, 2012
Great effort was made to include all clinical trials relevant for this mutation. However, the completeness of this information cannot be guaranteed.
Disclaimer: The information presented at MyCancerGenome.org is compiled from sources believed to be reliable. Extensive efforts have been made to make this information as accurate and as up-to-date as possible. However, the accuracy and completeness of this information cannot be guaranteed. Despite our best efforts, this information may contain typographical errors and omissions. The contents are to be used only as a guide, and health care providers should employ sound clinical judgment in interpreting this information for individual patient care.